Finanzen von Enveric Biosciences Inc (ENVB)ENVBEnveric Biosciences Inc

Evaluating the bottom line, Enveric Biosciences Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -235.48%, provide a clear picture of how effectively ENVB converts its operational activities into shareholder value.

In the context of the broader market, ENVB competes directly with industry leaders such as YCBD and PMCB. With a market capitalization of $6.18M, it holds a leading position in the sector. When comparing efficiency, ENVB's gross margin of N/A stands against YCBD's 53.29% and PMCB's N/A. Such benchmarking helps identify whether Enveric Biosciences Inc is trading at a premium or discount relative to its financial performance.

Enveric Biosciences has reported continuous losses, with net income reaching -$4,040,207 in Q4 2025 and a current ratio of 0.00 in Q2 2026, indicating liquidity issues. The company has a negative EPS of -0.76 for the latest quarter, reflecting challenges in profitability.